Your browser doesn't support javascript.
loading
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC.
Naigeon, Marie; Roulleaux Dugage, Matthieu; Danlos, François-Xavier; Boselli, Lisa; Jouniaux, Jean-Mehdi; de Oliveira, Caroline; Ferrara, Roberto; Duchemann, Boris; Berthot, Caroline; Girard, Lou; Flippot, Ronan; Albiges, Laurence; Farhane, Siham; Saulnier, Patrick; Lacroix, Ludovic; Griscelli, Frank; Roman, Gabriel; Hulett, Tyler; Marabelle, Aurélien; Cassard, Lydie; Besse, Benjamin; Chaput, Nathalie.
Afiliação
  • Naigeon M; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Roulleaux Dugage M; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Danlos FX; Faculté de Pharmacie, Université Paris-Saclay, Orsay, France.
  • Boselli L; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Jouniaux JM; Service d'Oncologie Médicale, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
  • de Oliveira C; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.
  • Ferrara R; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Duchemann B; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.
  • Berthot C; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015 and Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France.
  • Girard L; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Flippot R; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Albiges L; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Farhane S; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Saulnier P; Università Vita-Salute San Raffaele, Milan, Italy.
  • Lacroix L; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Griscelli F; Département d'oncologie thoracique et médicale, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne, AP-HP, Bobigny, France.
  • Roman G; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Hulett T; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Marabelle A; Faculté de Pharmacie, Université Paris-Saclay, Orsay, France.
  • Cassard L; Laboratoire d'Immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy, Villejuif, France.
  • Besse B; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Chaput N; Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
Sci Adv ; 9(45): eadh0708, 2023 11 10.
Article em En | MEDLINE | ID: mdl-37939189
ABSTRACT
Circulating senescent CD8+ T (T8sen) cells are characterized by a lack of proliferative capacities but retain cytotoxic activity and have been associated to resistance to immunotherapy in patients with advanced non-small cell lung cancer (aNSCLC). We aimed to better characterize T8sen and to determine which factors were associated with their accumulation in patients with aNSCLC. Circulating T8sen cells were characterized by a higher expression of SA-ßgal and the transcription factor T-bet, confirming their senescent status. Using whole virome profiling, cytomegalovirus (CMV) was the only virus associated with T8sen. CMV was necessary but not sufficient to explain high accumulation of T8sen (T8senhigh status). In CMV+ patients, the proportion of T8sen cells increased with cancer progression. Last, CMV-induced T8senhigh phenotype but not CMV seropositivity itself was associated with worse progression-free and overall survival in patients treated with anti-PD-(L)1 therapy but not with chemotherapy. Overall, CMV is the unique viral driver of T8sen-driven resistance to anti-PD-(L)1 antibodies in patients with aNSCLC.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Infecções por Citomegalovirus / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Infecções por Citomegalovirus / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França